Intel stock spikes after report of possible US government stake
LOS ANGELES - Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company with a market capitalization of $17.6 million, has presented new preclinical data on two investigational compounds at the recent American Association for Cancer Research Immuno-Oncology conference. The company’s stock has faced significant headwinds, declining over 56% in the past six months, though InvestingPro data shows it maintains a strong liquidity position with cash reserves exceeding debt obligations. The studies indicated potential advancements in cancer treatment through their KROS platform, involving compounds KROS 101 and KROS 401.
During the conference, which took place from February 23-26, Kairos Pharma revealed positive outcomes in melanoma and glioblastoma models using their compound KROS 101. The compound, a glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist, not only inhibited tumor growth but also enhanced the proliferation of essential T cells while reducing regulatory T cell growth. This resulted in sustained cytotoxicity against cancer cells without leading to T cell exhaustion, a common challenge in T cell immunotherapies.
Kairos Pharma also shared findings on KROS 401, a peptide inhibitor targeting macrophages within the tumor microenvironment. The preclinical study showed that KROS 401 could reprogram macrophages from a tumor-promoting state to a tumor-fighting state, significantly reducing tumor growth in glioma-bearing mice.
Dr. John Yu, CEO of Kairos Pharma, and Dr. Ram Murali, VP of Research and Development, expressed optimism about the data, highlighting the unique approach of their compounds in combating tumor growth and enhancing the immune system’s ability to fight cancer. While the company’s current financial health score ranks as weak according to InvestingPro analysis, its healthy current ratio of 2.84 suggests adequate resources to fund ongoing research and development efforts.
This news comes as Kairos Pharma continues to develop its oncology therapeutics portfolio, including the lead candidate ENV105, an antibody targeting CD105 to overcome drug resistance in various cancers. ENV105 is currently undergoing Phase 2 and Phase 1 clinical trials for prostate and lung cancers, respectively.
The company’s forward-looking statements, as included in the press release, emphasize aspirations and projections based on current information. However, these statements are subject to risks, uncertainties, and assumptions, and actual results may differ from expectations. Analysts maintain a positive outlook with a $9 price target, though investors should note that the company reported a net loss of $2.74 million in the last twelve months. For comprehensive financial analysis and additional insights, investors can access over 10 exclusive ProTips and detailed metrics through InvestingPro.
The information in this article is based on a press release statement from Kairos Pharma, Ltd.
In other recent news, Kairos Pharma announced the successful closure of a $3.5 million private investment in public equity (PIPE) transaction. The funds were raised through the sale of pre-funded and common warrants to accredited investors, with Boustead Securities, LLC and D. Boral (OTC:BOALY) Capital LLC serving as co-placement agents for the offering. This financial move is part of Kairos Pharma’s strategy to support ongoing clinical trials and the development of preclinical assets. Additionally, the company recently appointed Dr. Rahul Singhvi to its board of directors, following the resignation of Dr. Rosemary Mazanet for personal reasons. Dr. Singhvi brings a wealth of experience from the life sciences industry, having co-founded Resilience and held leadership roles at Flagship Pioneering and Novavax (NASDAQ:NVAX), Inc. Furthermore, Kairos Pharma outlined its achievements from 2024, including the completion of its Initial Public Offering and collaborations to advance its lead candidate, ENV105, for cancer treatment. The company plans to continue its Phase 2 clinical trial of ENV105 in prostate cancer and a Phase 1 trial in non-small cell lung cancer (NSCLC) in 2025. Initial safety data from these trials are anticipated in the first half of 2025 for prostate cancer and by the year’s end for NSCLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.